Changes in ocular signs and symptoms in patients switching from bimatoprost-Timolol to tafluprost-Timolol eye drops: An open-label phase IV study

Bourne R.R.A., Kaarniranta K., Lorenz K., Traverso C.E., Vuorinen J., Ropo A.

2019
BMJ Open

Therapeutic Area

Glaucoma
Categories

Clinical development

Affiliations

Cambridge University Hospitals, Cambridge, United Kingdom; Vision and Eye Research Unit, Anglia Ruskin University, Cambridge, United Kingdom; Department of Ophthalmology, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland; Department of Ophthalmology, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany; Clinica Oculistica Di.N.O.G.M.I., Università di Genova, Ospedale Policlinico San Martino, Genova, Italy; 4Pharma Ltd, Turku, Finland; Global Medical Affairs, Santen Oy, Helsinki, Finland

Related Publications

Metabolomic Profiling of Open-Angle Glaucoma Etiologic Endotypes: Tohoku Multi-Omics Glaucoma Study

Hanyuda A.; Raita Y.; Ninomiya T.; Hashimoto K.; Takada N.; Sato K.; Inoue J.; Koshiba S.; Tamiya G.; Narita A.; Akiyama M.; Omodaka K.; Tsuda S.; Yokoyama Y.; Himori N.; Yamamoto Y.; Taniguchi T.; Negishi K.; Nakazawa T.

Ocular Tissue Distribution of Omidenepag Isopropyl in Rabbits and Cynomolgus Monkeys

Yamamura K.; Mano H.; Fuwa M.; Ryoiwamura; Odani-Kawabata N.

Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial

Wang T.H.; Aung T.; Lu D.-W.; George R.; Senthil S.; Lu F.; Odani-Kawabata N.; Park K.H.

View all Glaucoma publications